B Lineage Cells and IgE in Allergic Rhinitis and CRSwNP and the Role of Omalizumab Treatment

被引:10
|
作者
Bai, Junqin [1 ]
Tan, Bruce K. [1 ,2 ,3 ]
机构
[1] Northwestern Univ Feinberg, Dept Otolaryngol, Sch Med, Chicago, IL USA
[2] Northwestern Univ Feinberg, Dept Med, Div Allergy & Immunol, Sch Med, Chicago, IL USA
[3] Northwestern Univ Feinberg, Dept Otolaryngol Head & Neck Surg, Sch Med, 676 N St Clair St,Suite 1325, Chicago, IL 60611 USA
关键词
allergic rhinitis; chronic rhinosinusitis with nasal polyps; type; 2; inflammation; B cell; plasma cell; germinal center; extrafollicular; autoantibody; immunoglobulin E; omalizumab; FC-EPSILON-RI; CHRONIC RHINOSINUSITIS; STAPHYLOCOCCUS-AUREUS; NASAL POLYPS; AIRWAY INFLAMMATION; ASTHMA; ANTIBODY; SUPERANTIGENS; ENTEROTOXINS; RESPONSES;
D O I
10.1177/19458924221147770
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
BackgroundAllergic rhinitis (AR) and chronic rhinosinusitis (CRS) are two prevalent nasal diseases where both type 2 inflammation and immunoglobulin E (IgE) may play important roles. Although they can exist independently or comorbidly, subtle but important differences exist in immunopathogenesis. ObjectiveTo summarize current knowledge of pathophysiological roles of B lineage cells and IgE in AR and CRS with nasal polyps (CRSwNP). MethodsSearched PubMed database, reviewed AR and CRSwNP-related literature, and discussed disease diagnosis, comorbidity, epidemiology, pathophysiology, and treatment. Similarities and differences in B-cell biology and IgE are compared in the 2 conditions. ResultsBoth AR and CRSwNP have evidence for pathological type 2 inflammation, B-cell activation and differentiation, and IgE production. However, distinctions exist in the clinical and serological profiles at diagnosis, as well as treatments utilized. B-cell activation in AR may more frequently be regulated in the germinal center of lymphoid follicles, whereas CRSwNP may occur via extrafollicular pathways although controversies remain in these initial activating events. Oligoclonal and antigen-specific IgE maybe predominate in AR, but polyclonal and antigen-nonspecific IgE may predominate in CRSwNP. Omalizumab has been shown efficacious in treating both AR and CRSwNP in multiple clinical trials but is the only Food and Drug Administration-approved anti-IgE biologic to treat CRSwNP or allergic asthma. Staphylococcus aureus frequently colonizes the nasal airway and has the ability to activate type two responses including B-cell responses although the extent to which it modulates AR and CRSwNP disease severity is being investigated. ConclusionThis review highlights current knowledge of the roles of B cells and IgE in the pathogenesis of AR and CRSwNP and a small comparison between the 2 diseases. More systemic studies should be done to elevate the understanding of these diseases and their treatment.
引用
收藏
页码:182 / 192
页数:11
相关论文
共 50 条
  • [21] Clinical Efficacy and Safety of Omalizumab in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis of Randomized Clinical Trials
    Yu, Chenjie
    Wang, Kaijian
    Cui, Xinyan
    Lu, Ling
    Dong, Jianfei
    Wang, Maohua
    Gao, Xia
    AMERICAN JOURNAL OF RHINOLOGY & ALLERGY, 2020, 34 (02) : 196 - 208
  • [22] Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
    Busse, W
    Corren, J
    Lanier, BQ
    McAlary, M
    Fowler-Taylor, A
    Della Cioppa, G
    van As, A
    Gupta, N
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 108 (02) : 184 - 190
  • [23] Local production and detection of (specific) IgE in nasal B-cells and plasma cells of allergic rhinitis patients
    KleinJan, A
    Vinke, JG
    Severijnen, LWFM
    Fokkens, WJ
    EUROPEAN RESPIRATORY JOURNAL, 2000, 15 (03) : 491 - 497
  • [24] Anti-IgE monoclonal antibody, omalizumab: a new treatment for allergic asthma
    Chung, KF
    EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (02) : 439 - 446
  • [25] The role of omalizumab in the treatment of adults with severe allergic asthma
    Kristan, Sabina Skrgat
    ZDRAVNISKI VESTNIK-SLOVENIAN MEDICAL JOURNAL, 2013, 82 (03): : 142 - 149
  • [26] A treatment for allergic rhinitis: a view on the role of levocetirizine
    Holgate, S
    Powell, R
    Jenkins, M
    Ali, O
    CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (07) : 1099 - 1106
  • [27] The Role of Anti-IgE Therapy in Combination with Allergen Specific Immunotherapy for Seasonal Allergic Rhinitis
    Philippe Stock
    Claudia Rolinck-Werninghaus
    Ulrich Wahn
    Eckard Hamelmann
    BioDrugs, 2007, 21 : 403 - 410
  • [28] The Role of Small Extracellular Vesicles and MicroRNAs in the Diagnosis and Treatment of Allergic Rhinitis and Nasal Polyps
    Liu, Yiting
    Sha, Jichao
    Meng, Cuida
    Zhu, Dongdong
    MEDIATORS OF INFLAMMATION, 2022, 2022
  • [29] Omalizumab for the Treatment of Inadequately Controlled Allergic Rhinitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
    Tsabouri, Sophia
    Tseretopoulou, Xanthippi
    Priftis, Konstantinos
    Ntzani, Evangelia E.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2014, 2 (03) : 332 - +
  • [30] A Nonsynonymous FCER1B SNP is Associated with Risk of Developing Allergic Rhinitis and with IgE Levels
    Amo, Gemma
    Garcia-Menaya, Jesus
    Campo, Paloma
    Cordobes, Concepcion
    Plaza Seron, M. Carmen
    Ayuso, Pedro
    Esguevillas, Gara
    Blanca, Miguel
    Agundez, Jose A. G.
    Garcia-Martin, Elena
    SCIENTIFIC REPORTS, 2016, 6